(NASDAQ: ATRA) Atara Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.
Atara Biotherapeutics's earnings in 2026 is -$16,688,000.On average, 6 Wall Street analysts forecast ATRA's earnings for 2026 to be -$7,293,400, with the lowest ATRA earnings forecast at -$12,492,934, and the highest ATRA earnings forecast at $2,140,040. On average, 6 Wall Street analysts forecast ATRA's earnings for 2027 to be $4,112,450, with the lowest ATRA earnings forecast at $2,016,576, and the highest ATRA earnings forecast at $5,585,986.
In 2028, ATRA is forecast to generate $1,569,898 in earnings, with the lowest earnings forecast at -$4,525,000 and the highest earnings forecast at $12,647,515.